Skip to main content
. Author manuscript; available in PMC: 2017 Oct 11.
Published in final edited form as: J Hypertens. 2016 May;34(5):1005–1010. doi: 10.1097/HJH.0000000000000870

TABLE 1.

Baseline characteristics and the results of bivariate analysis for favorable SBP reduction (≥ 10 mmHg) of patients treated with spironolactone

Parameters Favorable SBP Reduction
All (n = 79) Yes (n = 54) No (n = 25) P value
Age (years), mean ± SD   56.2 ± 12.3   57.7 ± 11.6   53.0 ± 13.5 0.12
Women, n (%) 42.0 (53.2%) 30.0 (55.6%) 7.0 (28.0%) 0.02
African-Americans, n (%) 43.0 (55.8%) 26.0 (50.0%) 17.0 (68.0%) 0.14
BMI (kg/m2), mean ± SD 34.5 (7.0%) 34.8 (7.2%) 33.9 (6.9%) 0.60
Obesity (BMI > 30Kg/m2), n (%) 57.0 (76.0%) 40.0 (76.9%) 17.0 (73.9%) 0.78
SBP (mmHg), mean ± SD 155.0 ± 23.5 157.7 ± 23.6 149.0 ± 22.5 0.13
DBP (mmHg), mean ± SD   85.2 ± 14.9   84.2 ± 14.3   87.4 ± 16.3 0.38
Year(s) of hypertension, mean ± SD   17.4 ± 10.7   17.7 ± 10.1   16.6 ± 12.0 0.68
Number of antihypertensive medications, mean ± SD   4.1 ± 1.0   4.1 ± 1.1   3.9 ± 1.0 0.50
SBP at follow-up (mmHg), mean ± SD 139.5 ± 24.9 132.7 ± 21.1 154.1 ± 26.2 NA
Mean SBP reduction at Follow-up (mmHg), mean ± SD   15.5 ± 20.7 −25.1 ± 15.8   5.08 ± 14.1 NA

NA, not assessed.